+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 60Years
All Genders
ID05182463

Study of Peginterferon Alpha-2b and Nucleoside Analogs Treatment for Adults with Inactive Chronic Hepatitis B

Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2025-05-01

5000

Participants Needed

1

Research Sites

154 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying treatments for inactive chronic hepatitis B CHB, a condition affecting millions worldwide and particularly common in China from perinatal infection. The study aims to compare the effectiveness of different antiviral treatment plans, including peginterferon and nucleoside analogs, to find factors leading to a functional cure for inactive CHB patients. This real-world, multi-center prospective study addresses variations in current treatment guidelines and the increasing desire for therapy among patients. The study evaluates several antiviral regimens one using oral nucleoside analogs like Entecavir or Tenofovir for 12-24 weeks followed by peginterferon alfa-2b, combination therapy of nucleoside analogs with peginterferon for up to 96 weeks, peginterferon alone for up to 96 weeks, or nucleoside analogs alone for up to 96 weeks. Each treatment group has a follow-up period of 144 weeks to monitor long-term outcomes. Participants will undergo regular monitoring throughout treatment and follow-up, including blood tests to measure hepatitis B surface antigen HBsAg clearance, serological conversion, and viral DNA levels over up to 96 weeks of treatment and 144 weeks of follow-up. Researchers will also track safety and adherence during the study. The total study duration for each participant, including follow-up, may extend beyond two years to evaluate sustained treatment responses.

CONDITIONS

Brief Title

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Research Team

Z

Zhishuo Mo, Master

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here